Gluscan (Fludeoxyglucose (18f))

Gluscan is employed as a diagnostic imaging agent in positron emission tomography (PET) to assess metabolic activity in various clinical contexts.

• Oncologic PET imaging for tumor detection, staging, and therapeutic monitoring.
• Cardiac PET imaging to evaluate myocardial viability and perfusion.
• Neurologic PET imaging for assessment of epilepsy foci, dementia, and other brain disorders.
• Research applications involving quantitative measurement of glucose metabolism in clinical trials.
• Evaluation of inflammatory diseases where increased metabolic activity may indicate active inflammation.

Adverse reactions to Gluscan are generally infrequent, but they can be categorized by frequency and severity.

Common

• Transient flushing or warmth sensation at the injection site.
• Mild nausea or vomiting shortly after administration.
• Short‑lasting headache or dizziness.
• Temporary metallic taste in the mouth.
• Mild fatigue or feeling of weakness.
• Minor injection site discomfort.

Serious

• Allergic reactions ranging from urticaria to anaphylaxis.
• Severe hypoglycemia in patients with impaired glucose regulation.
• Radiation‑related tissue injury in rare high‑dose exposures.
• Cardiac arrhythmia triggered by metabolic stress.
• Persistent neurological symptoms such as seizures in susceptible individuals.

Prior to administering Gluscan, clinicians should evaluate patient-specific factors and follow safety guidelines to minimize risks.

• Verify blood glucose level is within an acceptable range before injection.
• Assess for known hypersensitivity to fluorodeoxyglucose or any component of the formulation.
• Consider pregnancy and lactation status; use only if the diagnostic benefit outweighs potential fetal exposure.
• Ensure appropriate radiation protection measures for staff and nearby individuals.
• Adjust dosing for pediatric patients according to weight‑based protocols when applicable.
• Review recent administration of other radiopharmaceuticals to avoid cumulative radiation dose.

Gluscan may interact with certain medications or conditions that affect glucose metabolism or radiation exposure.

Avoid

• Concurrent use of high‑dose insulin or oral hypoglycemic agents that could cause severe hypoglycemia.
• Administration of other radiopharmaceuticals within a short interval, which may increase cumulative radiation dose.

Use with caution

• Patients receiving chemotherapy or targeted therapies that alter tumor metabolism.
• Use in individuals with renal impairment affecting clearance of the tracer.
• Concurrent contrast agents for CT may affect image interpretation; schedule appropriately.
• Beta‑blockers or other drugs influencing myocardial glucose uptake in cardiac studies.
• Medications that significantly alter systemic glucose levels, such as corticosteroids.